4SC AG's revenue for the
six
months ended in Dec. 2023 was €0.18 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.30 Mil.
4SC AG's Revenue per Share for the
six
months ended in Dec. 2023 was €0.02.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.03.
Warning Sign:
4SC AG revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of 4SC AG was -30.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -50.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -43.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -29.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, 4SC AG's highest 3-Year average Revenue per Share Growth Rate was 101.40% per year. The lowest was -50.20% per year. And the median was -32.10% per year.
4SC AG Revenue Historical Data
The historical data trend for 4SC AG's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 4SC AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4SC AG's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4SC AG's Revenue distribution charts can be found below:
* The bar in red indicates where 4SC AG's Revenue falls into.
4SC AG Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4SC AG (LTS:0R6U) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
4SC AG Revenue Related Terms
Thank you for viewing the detailed overview of 4SC AG's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0R6U has been successfully added to your 